Mycapssa and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with Mycapssa (octreotide).
octreotide food
Moderate Food Interaction
MONITOR: Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications. Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat. Clinical data are limited, however. In case reports, octreotide has been reported to reduce the relative bioavailability of cyclosporine. Transplant rejection and significant reductions in cyclosporine levels, sometimes to undetectable levels, have been reported in association with the interaction. Vitamin K absorption was not affected when concomitantly administered with lanreotide according to the manufacturer.
MANAGEMENT: Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs. Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.
References
- Landgraf R, Landgraf-Leurs MM, Nusser J, et al. "Effect of somatostatin analogue (SMS201-995) on cyclosporine levels." Transplantation 44 (1987): 724-5
- Ho PJ, Boyajy LD, Greenstein E, Barkan AL "Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly." Dig Dis Sci 38 (1993): 309-15
- Katz MD, Erstad BL "Octreotide, a new somatostatin analogue." Clin Pharm 8 (1989): 255-73
- "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation PROD (2001):
- "Product Information. Somatuline Depot (lanreotide)." Ipsen Inc (2007):
Mycapssa drug interactions
There are 154 drug interactions with Mycapssa (octreotide).
Mycapssa disease interactions
There are 7 disease interactions with Mycapssa (octreotide) which include:
- renal dysfunction
- gallbladder/biliary dysfunction
- glucose intolerance
- heart disease
- hepatic impairment
- thyroid dysfunction
- vitamin B12 deficiency
More about Mycapssa (octreotide)
- Mycapssa consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: somatostatin and somatostatin analogs
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.